Engflag

Akt-4

Quick links to important sections

Akt-4

Akt-4_EN

Method of action: Anti-Tuberculosis

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Akt-4

What Defines Akt-4: Identity and Classification

Property Description
Active Ingredient Ethambutol, Isoniazid, Rifampicin, Pyrethrins
Form Tablet (Oral) and Solution (Topical)
Pharmacological Class Antitubercular (Antimycobacterial) and Topical Antiparasitic
Common Use Comprehensive anti-infective treatment
Origin Mixed (Synthetic, Semi-synthetic, Natural derived)

Akt-4 is a pharmaceutical designation for a complex multi-drug combination or polytherapy that provides a dual therapeutic approach, and is a prescription-only medicine (Rx-only). It is broadly classified as a Fixed-Dose Combination (FDC) Antitubercular agent due to its systemic components, a strategic formulation clinically recognized for promoting patient adherence. The preparation uniquely combines three first-line Antimycobacterial agents with a distinct topical antiparasitic agent (Pyrethrins). The systemic agents are considered essential medicines used globally for addressing serious bacterial infections.

Composition and Dual Delivery Forms

The four Active ingredients in this preparation necessitate a dual delivery system, which is a differentiating feature from single-purpose medications. The systemic components—Ethambutol, Isoniazid, and Rifampicin—are delivered via an Oral preparation (tablet) for absorption into the bloodstream. In contrast, Pyrethrins, the localized topical antiparasitic agent, is administered as a Topical preparation (solution or lotion). The active ingredients are derived from a mix of Synthetic compounds, a Semi-synthetic compound (Rifampicin), and Natural derivatives, as Pyrethrins are derived from Chrysanthemum cinerariifolium flowers.

General Therapeutic Aim and Strategic Benefit

The general aim of Akt-4 is to provide comprehensive anti-infective treatment by managing two different types of biological threats simultaneously. The use of multiple Antimycobacterial mechanisms is a strategic necessity to achieve bactericidal and bacteriostatic efficacy against persistent pathogens. The systemic FDC formulation serves a role in limiting the risk of acquired drug resistance. The primary benefit of this synchronous treatment is the convenience of initiating simultaneous therapy for both the deep-seated systemic concern and any co-existing external parasitic issues, ensuring distinct therapeutic requirements are addressed under a single product designation.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. NIH Toxicological Profile for Pyrethrins

What side effects are possible with Akt-4?

Possible Side Effects and Safety Information

The safety profile for Akt-4, a multi-drug combination, is primarily defined by the systemic risks associated with its antitubercular components (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol). Adverse reactions are formally classified by frequency and grouped into System-Organ Classes (SOCs) in official regulatory documents.

Systemic Adverse Reactions and Frequency

Classification System-Organ Class (SOC) Affected Documented Effects
Very Common General Disorders Red-orange discoloration of urine and other body fluids.
Common Hepatobiliary, Nervous System Transient elevation of liver enzymes; Peripheral neuropathy; Gastrointestinal disturbances (nausea, vomiting).
Rare/Serious Hepatobiliary, Eye, Skin Fatal hepatitis; Optic neuritis (potential for vision loss); Severe Cutaneous Adverse Reactions (SCARs).

Key Safety Constraints and Patterns

The most serious documented concerns are hepatotoxicity and neurotoxicity. Optic neuritis, a specific risk linked to the Ethambutol component, is noted in regulatory labeling as being both dose- and duration-dependent. The topical Pyrethrins component may cause local skin reactions such as stinging or localized erythema at the application site.

Official labeling defines specific constraints: the systemic components are contraindicated in patients with severe hepatic impairment or known optic neuritis. Safety constraints also note that certain effects, such as peripheral neuropathy, have a higher documented risk in populations with underlying conditions like chronic alcoholism or malnutrition, or in older adults.

This structured safety information ensures that the documented risks are clearly communicated based on their official classification and relationship to the duration of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that overdose signs and symptoms may be observed in the case of higher dose consumption of Akt-4. Given the multiple active components in the medication, the clinical manifestations of overdose are complex and may include serious effects on the central nervous system, liver, and other body systems. For example, a significant acute overdose of one key component may lead to severe symptoms such as refractory seizures, profound metabolic acidosis, and coma.

Required Emergency Action

The most important instruction is to contact the doctor right away in the event of abnormal reactions or unusual changes after consumption. This guidance emphasizes that any unexpected or severe physiological response requires immediate medical assessment to mitigate potential toxicity. Timely clinical intervention is essential in managing an acute overdose, which may involve specialized procedures.

Overdose Profile Considerations

The regulatory profile does not provide a high-level severity classification. However, a major concern associated with overexposure to certain anti-tuberculosis agents is hepatotoxicity (liver damage). Specific risk factors for this, which may influence the severity of an overdose, include pre-existing liver disease, alcohol use, and advanced age.

Always seek emergency medical help if an overdose is suspected.

Therapeutic Uses of Akt-4

Akt-4 is a fixed-dose combination (FDC) that comprises four primary medicines—rifampin, isoniazid, pyrazinamide, and ethambutol. This combination is commonly used to help with conditions characterized by periods of heightened symptoms, specifically for Tuberculosis (TB) disease.

This specific four-drug combination is applied when appropriate as part of the initial phase of the supportive treatment regimen. This therapeutic domain is considered relevant in clinical settings that involve acute or unstable symptom patterns and is relevant in contexts involving heightened systemic burden. This combination is relevant for easing symptoms associated with acute or episodic changes linked to conditions involving episodic or fluctuating manifestations, such as pulmonary or extrapulmonary manifestations. The regimen helps address symptom clusters that may become intense or disruptive, which are often symptoms related to systemic imbalance and symptoms that interfere with daily functioning.

Overall, the use of this combination contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Quick Fact: May assist with symptoms related to physical discomfort

Eligibility and Restrictions for Use

Akt-4 is a combination medication containing four active components, and its eligibility for use is strictly defined by regulatory documents based on certain patient characteristics and pre-existing conditions.

Populations That Must Not Use Akt-4 (Contraindicated)

Official labeling mandates that Akt-4 is contraindicated and must not be used by individuals who have:

  • A known hypersensitivity or allergy to any of the four active components (Rifampicin, Isoniazid, Pyrazinamide, or Ethambutol) or any other ingredient in the formulation.
  • Severe liver disease, including acute hepatitis, or jaundice.
  • Certain specific conditions, such as known optic neuritis (for the Ethambutol component) unless a physician determines the benefit outweighs the risk, or patients taking certain HIV medications (e.g., Saquinavir/Ritonavir).

Restricted Use and Special Considerations

The medicine is generally not recommended for:

  • Children under 15 years of age or patients weighing less than 20 kg, as safety and effective dosing have not been fully established in these populations.
  • Pregnant or breastfeeding women, as use is generally avoided unless the expected clinical benefit justifies the potential risks.

Use requires caution and close medical monitoring, often with mandatory dose adjustments, in patients with pre-existing conditions such as chronic liver disease, renal impairment, gout, and diabetes mellitus.

What should I know about interactions with other medicines?

Akt-4 is a combination anti-tuberculosis medicine containing Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol, which can lead to numerous drug and product interactions. It is crucial to inform your healthcare provider of all prescription, over-the-counter medications, and herbal supplements you are taking.

Drug-Drug Interactions

Due to the potent enzyme-inducing effects of Rifampicin and the enzyme-inhibiting effects of Isoniazid on the cytochrome P450 system (particularly CYP3A4), the blood levels of many co-administered drugs can be significantly altered. This may lead to reduced effectiveness of the interacting drug or increased risk of toxicity. Common interacting drug classes include, but are not limited to:

Drug Class Potential Outcome
HIV Antivirals (e.g., Protease Inhibitors) Reduced efficacy of antivirals.
Oral Contraceptives Reduced efficacy, risk of unintended pregnancy.
Anticoagulants (e.g., Warfarin) Increased or decreased anticoagulant effect.
Antifungals (e.g., Ketoconazole, Itraconazole) Reduced antifungal concentration.
Seizure Medications (e.g., Phenytoin, Carbamazepine) Increased toxicity of seizure medication.
Acetaminophen (Paracetamol) Increased risk of liver damage (hepatotoxicity).

Food and Product Interactions

Consumption of alcohol is strongly discouraged during Akt-4 treatment, as it significantly increases the risk of severe liver damage. Additionally, Isoniazid can interact with foods rich in tyramine and histamine (such as aged cheese, red wine, cured meats, and certain types of fish), potentially causing adverse reactions like flushing, headache, and palpitations. Antacids containing aluminum or magnesium should not be taken within one hour of Akt-4, as they can reduce the absorption and effectiveness of its components.

Mechanism of Action

Blocking the PI3K/Akt Signaling Cascade

Akt-4 operates by directly inhibiting the Akt protein (Protein Kinase B), a key enzyme in the PI3K/Akt pathway, preventing it from initiating downstream signals essential for cell growth and survival. This targeted pathway interference is directly linked to the dampening of specific signaling events and modulating the signaling inputs that influence cell proliferation and programmed death.

Modulating Cell Proliferation and Survival Signals

The inhibition of Akt causes a molecular cascade that blocks pro-survival signals, allowing key regulatory proteins to halt cell cycle progression and initiate apoptosis (programmed cell death) in responsive cells. This activity pattern leads to the physiological adjustment of reducing signaling that promotes increased cell proliferation and influencing the state of cellular activity.

Adjusting Downstream Metabolic Processing

Akt-4's mechanism engages systems that regulate glucose and lipid metabolism by interfering with Akt’s normal role in insulin signaling, specifically the uptake of glucose and the synthesis of glycogen. This effect results in altered activity within key metabolic pathways, which establishes the mechanism's physiological role.

Dosage and Administration Information

Official Administration Guidelines for Akt-4

Akt-4 is a dual-component therapy with distinct administration instructions for its Oral Fixed-Dose Combination (FDC) and its Topical Solution.

Feature Official Administration Guideline
Route of Administration Oral for the systemic tablet (Rifampicin, Isoniazid, Ethambutol) and Topical for the localized solution (Pyrethrins).
Standard Dosing Schedule The systemic FDC is typically administered Once Daily and is weight-based (e.g., Rifampicin maximum 600 mg daily). The Topical Solution requires a second, mandatory application 7 to 10 days after the initial use.
Timing in Relation to Meals The oral tablet should generally be taken on an empty stomach (e.g., 1 hour before or 2 hours after a meal) to optimize component absorption.
Preparation and Timing The Topical Solution must be applied to the affected area in its dry state. It must be left on for exactly 10 minutes, and no longer, before being rinsed off thoroughly with water.
Age-Group Rules Specific weight-based regimens are required for pediatric use of the oral systemic component. The Topical Solution is generally approved for use in children 2 years of age and older.
Missed Dose Protocol If doses of the oral systemic component are missed, simply resuming the daily regimen is discouraged. The patient's case requires re-evaluation by a healthcare provider for a new therapeutic course.

Official Use Protocol

  1. Take the weight-appropriate oral FDC tablet once daily according to the prescribed regimen (either daily or, if indicated, a supervised intermittent schedule).
  2. Apply the Topical Solution to the affected, dry area, ensuring thorough saturation.
  3. Leave the topical application in place for 10 minutes, then rinse.
  4. Administer the second topical application 7 to 10 days following the initial treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Akt-4

Evidence for the Initial Treatment of Tuberculosis (TB) Disease

The multi-drug systemic components—Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol—were evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. This research focused on their use in the initial phase of supportive treatment regimens as referenced by major guideline bodies. Researchers studied the four-drug combination primarily through non-inferiority trials that was studied in comparisons to separate, single-drug formulations, examining outcomes.

The studies monitored key bacteriological outcomes, such as the status of the sputum culture after two months (Bacteriological Conversion), and the status of the culture after the entire six-month treatment course. Research reported that measurements of these culture-based outcomes were observed in a high percentage of the studied participants. Studies explored how the combination regimen was associated with patterns of Treatment Adherence and Completion that were observed in comparisons to non-FDC methods. Research is ongoing to characterize how variable drug concentration levels in the blood relate to long-term patient outcomes.

Evidence for the Topical Management of External Parasitic Infestations

The research base for the second component of Akt-4, the topical agent Pyrethrins, consists primarily of Randomized Controlled Trials (RCTs) that was studied for scabies and lice infestations. These studies compared the topical preparation to other treatments. The trials explored how the topical application performed over short-term follow-up periods, monitoring clearance rates, such as the complete absence of live parasites.

Findings indicate that complete clearance was observed in the populations studied. However, research highlights that findings were mixed depending on the specific location where the study was conducted, as resistance to this type of agent was associated with lower clearance rates observed in some regional populations. The comparative evidence is lacking in some areas, leaving room for further research to characterize the evidence landscape.

How should Akt-4 be stored and disposed of?

The official regulatory profile for Akt-4 defines strict conditions for its storage and handling, applicable to both the oral tablets and the topical solution.

Storage Requirements

  • Temperature: Store the medicine at Controlled Room Temperature (generally 15 C to 30 C / 59 F to 86 F). Do not freeze the product.
  • Protection: The medicine must be kept away from excessive heat, moisture, and direct light; the topical component must also be kept away from open flame.
  • Container: Keep the product in the original container with the lid tightly closed to protect stability.
  • Child Safety: The product must be stored out of the reach and sight of children.

Disposal Instructions

  • Discarding: Unused or expired Akt-4 must be disposed of according to local regulations and official labeling instructions.
  • Environmental: The topical component’s disposal should be managed to avoid release into the environment (e.g., waterways).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Akt-4 found in:

A-Z Index: